ARTICLE | Company News

Priority Reviews for Eisai's lenvatinib and rufinamide

October 15, 2014 1:45 AM UTC

Eisai Co. Ltd. (Tokyo:4523) said FDA accepted for filing and granted Priority Review to an NDA for lenvatinib ( E7080) and an sNDA for rufinamide ( E2080).

Eisai is seeking approval of lenvatinib to treat progressive, radioiodine-refractory differentiated thyroid cancer. The compound is a once-daily oral inhibitor of multiple VEGF receptor tyrosine kinases. Partner SFJ Pharmaceuticals Inc. (Pleasanton, Calif.) is eligible for milestone payments if the compound is approved. ...